Back to Search
DAVID SARGENT, MD
MD
Diagnostic Radiology Physician
NPI: 1821477175IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Diagnostic Radiology PhysicianPrimary
Radiology — Diagnostic Radiology
Code: 2085R0202X
20222(NH)042.0014623(VT)
CMS Specialties
PrimaryDIAGNOSTIC RADIOLOGY
Education
OTHER
Class of 2015
Research & Publications (20)
Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
PMID 19622902·Oncology·2009
3-trial
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.
PMID 19636001·J Clin Oncol·2009
4-observational
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma.
PMID 19577568·Gastroenterology·2009
8-other
Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial.
PMID 19564531·J Clin Oncol·2009
3-trial
Importance of randomization in early clinical trials.
PMID 19521327·Clin Adv Hematol Oncol·2009
8-other
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
PMID 19597023·J Clin Oncol·2009
8-other
Clinical implications of microsatellite instability in sporadic colon cancers.
PMID 19444104·Curr Opin Oncol·2009
6-review
Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144.
PMID 19423501·Clin Colorectal Cancer·2009
8-other
Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.
PMID 19414682·J Clin Oncol·2009
8-other
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.
PMID 19390940·Int J Clin Oncol·2009
6-review
Current issues in oncology drug development, with a focus on Phase II trials.
PMID 19384696·J Biopharm Stat·2009
8-other
Clinical trial designs for predictive biomarker validation: one size does not fit all.
PMID 19384694·J Biopharm Stat·2009
8-other
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
PMID 19380443·J Clin Oncol·2009
3-trial
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.
PMID 19470929·J Clin Oncol·2009
4-observational
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.
PMID 19255311·J Clin Oncol·2009
1-meta
Early stopping for benefit in National Cancer Institute-sponsored randomized Phase III trials: the system is working.
PMID 19237627·J Clin Oncol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 3 locations total
- Address
- 2900 LAMB CIR
CHRISTIANSBURG, VA 24073 - Phone
- (540) 731-2810
Quick Facts
- NPI
- 1821477175
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 3
- Years in Practice
- 11
- Publications
- 20
Are you this provider?
Claim Your Profile